RBC Capital raised the firm’s price target on HCA Healthcare (HCA) to $555 from$525 and keeps an Outperform rating on the shares. The firm was “pleased” to see a strong reaction in shares after a solid Q4 result and strong initial 2026 guidance, the analyst tells investors in a research note. The 2026 full year outlook reflects better than expected core performance as well as $400M in savings from resiliency efforts that more than offset the ePTC expiry and lower contribution from state supplemental progra ...